Clues to quality of journals
Open Access Policy of Helmholtz Association 2016
CC Licencences
Publication Metrics
Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Statistics (last 5 years)
OA Publications
Submit Publication
Import publication from...
Report missing publication
Contact persons
Help
Text
Endnote (RIS)
BibTeX
DOI
 |
|
as soon as is submitted to ZB.
Towards curative therapy of chronic viral hepatitis.
Z. Gastroenterol. 57, 61-73 (2019)
Persistent infection with hepatitis viruses is a major medical burden that unfortunately is often ignored in the general public. This results in a massive under-diagnosis of these infections. According to the world health organization, the number of people dying every year from the consequence of hepatitis virus infection has surpassed the death rate caused by malaria and HIV and is equivalent to the one of tuberculosis. These numbers call for more intense efforts to devise more effective, ideally curative therapies that must become as widely accessible as they are e.g. for HIV infected individuals. A major step forward has been the development of curative antiviral therapy for chronic hepatitis C. In the case of hepatitis D virus, new drug candidates have been developed that should receive conditional approval very soon. For chronic hepatitis B, development is lagging behind but thanks to a re-emerging interest of pharmaceutical industry that was triggered by the success of hepatitis C therapy and the availability of novel infection systems, new attempts towards curative approaches for this highly prevalent infection are undertaken. Here we summarize the current status of therapy development for chronic viral hepatitis that ultimately aims at cure.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Times Cited
Scopus
Cited By
Cited By
Altmetric
1.236
0.681
7
8
Annotations
Special Publikation
Hide on homepage
Publication type
Article: Journal article
Document type
Scientific Article
Keywords
Viral Hepatitis ; Hepatitis Virus ; Hepatitis B ; Hepatitis D ; Hepatitis C ; Curative Therapy; Chronic Delta-hepatitis; Pegylated Interferon Alpha-2a; Ns3 Protease Inhibitor; B-virus; T-cells; Hepatocellular-carcinoma; Antiviral Activity; Envelope Proteins; Immune Tolerance; Natural-history
Language
english
Publication Year
2019
HGF-reported in Year
2019
ISSN (print) / ISBN
0044-2739
e-ISSN
1439-7803
Quellenangaben
Volume: 57,
Issue: 1,
Pages: 61-73
Publisher
Thieme
Publishing Place
Rudigerstr 14, D-70469 Stuttgart, Germany
Reviewing status
Peer reviewed
Institute(s)
Institute of Virology (VIRO)
POF-Topic(s)
30203 - Molecular Targets and Therapies
Research field(s)
Immune Response and Infection
PSP Element(s)
G-502700-003
WOS ID
WOS:000455675700020
Scopus ID
85059941079
Erfassungsdatum
2019-02-28